CDXS (Codexis) Interest Expense : $-5.91 Mil (TTM As of Sep. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Codexis Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Codexis's interest expense for the three months ended in Sep. 2024 was $ -4.92 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was $-5.91 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Codexis's Operating Income for the three months ended in Sep. 2024 was $ -16.56 Mil. Codexis's Interest Expense for the three months ended in Sep. 2024 was $ -4.92 Mil. Codexis did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Codexis Interest Expense Historical Data

The historical data trend for Codexis's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Codexis Interest Expense Chart

Codexis Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

Codexis Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Expense	Get a 7-Day Free Trial															-3.90	-	-	-0.99	-4.92

Codexis Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.91 Mil.

Codexis (NAS:CDXS) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Codexis's Interest Expense for the three months ended in Sep. 2024 was $-4.92 Mil. Its Operating Income for the three months ended in Sep. 2024 was $-16.56 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was $37.77 Mil.

Codexis's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

Codexis did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Codexis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codexis Inc (NAS:CDXS) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

0I0X:UK 4QK:Germany

Address

200 Penobscot Drive, Redwood, CA, USA, 94063

Website

https://www.codexis.com

Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.

Executives

Byron L Dorgan	director	C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Kevin Norrett	officer: Chief Operating Officer	C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Margaret Nell Fitzgerald	officer: See Remarks	ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Sriram Ryali	officer: Chief Financial Officer	C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Stephen George Dilly	director, officer: See Remarks	C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
John J Nicols	director, officer: President and CEO	ALBEMARLE CORP, 451 FLORIDA ST, BATON ROUGE LA 70801
H Stewart Parker	director
Rahul Singhvi	director	246 HOLLY DRIVE, CHALFONT PA 18914
Dennis P Wolf	director	1101 EAST MEADOW DR, PALO ALTO CA 94303
Patrick Y Yang	director	C/O GENENTECH INC, 1 DNA WAY,MS 49,ATTN:K.STRAND OR J.BERRY, SOUTH SAN FRANCISCO CA 94080-4990
Bernard J Kelley	director
Esther Martinborough	director	C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Jennifer Aaker	director	C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Alison Moore	director	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Thomas R Baruch	director	1 LETTERMAN DRIVE, BUILDING C, SUITE CM500, SAN FRANCISCO CA 94129